(TCMD) Tactile Systems Technology - Ratings and Ratios
Compression Device, Lymp
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 54.8% |
| Value at Risk 5%th | 73.5% |
| Relative Tail Risk | -18.40% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.08 |
| Alpha | 65.19 |
| CAGR/Max DD | 0.53 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.334 |
| Beta | 0.564 |
| Beta Downside | 0.502 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.25% |
| Mean DD | 35.11% |
| Median DD | 43.41% |
Description: TCMD Tactile Systems Technology January 01, 2026
Tactile Systems Technology, Inc. (NASDAQ:TCMD) develops pneumatic-compression medical devices targeting underserved chronic conditions in the U.S., primarily lymphedema and venous disorders. Its flagship products include the Flexitouch Plus system for home-based lymphedema therapy, the Entre Plus portable compressor for chronic venous insufficiency and leg ulcers, and the Nimbl platform for upper-extremity lymphedema. Complementary offerings are the Kylee mobile app for symptom tracking and clinician communication, and the AffloVest high-frequency chest-wall oscillation vest for patients with bronchiectasis, cystic fibrosis, or neuromuscular disease.
Key performance indicators (as of Q3 2024) show TCMD generated $27.5 million in revenue, a 12 % year-over-year increase driven by expanding Medicare coverage for pneumatic compression therapy. The lymphedema device market is estimated at $1.2 billion in 2024 with a compound annual growth rate (CAGR) of roughly 6 %, reflecting an aging population and rising prevalence of chronic vascular conditions. Additionally, the company’s gross margin improved to 58 % after cost-optimization initiatives in its supply chain.
Sector-wide, health-care equipment firms are benefiting from heightened reimbursement pressure and a shift toward home-based care, which aligns with TCMD’s at-home therapy focus. However, competitive dynamics from larger medical-device players and potential policy changes to Medicare reimbursement rates remain material risks.
For a deeper quantitative view, the ValueRay platform offers granular analyst models on TCMD’s financials and peer benchmarks.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (18.2m TTM) > 0 and > 6% of Revenue (6% = 18.7m TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA 1.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.81% (prev 43.93%; Δ -11.12pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 41.8m > Net Income 18.2m (YES >=105%, WARN >=100%) |
| Net Debt (-49.2m) to EBITDA (35.4m) ratio: -1.39 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (22.5m) change vs 12m ago -7.18% (target <= -2.0% for YES) |
| Gross Margin 74.96% (prev 72.86%; Δ 2.10pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 113.9% (prev 99.07%; Δ 14.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.57 (EBITDA TTM 35.4m / Interest Expense TTM 2.99m) >= 6 (WARN >= 3) |
Altman Z'' 4.71
| (A) 0.39 = (Total Current Assets 141.4m - Total Current Liabilities 39.2m) / Total Assets 259.2m |
| (B) 0.17 = Retained Earnings (Balance) 44.3m / Total Assets 259.2m |
| (C) 0.10 = EBIT TTM 28.6m / Avg Total Assets 273.5m |
| (D) 0.82 = Book Value of Equity 44.3m / Total Liabilities 54.2m |
| Total Rating: 4.71 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.44
| 1. Piotroski 8.0pt |
| 2. FCF Yield 6.59% |
| 3. FCF Margin 12.67% |
| 4. Debt/Equity 0.08 |
| 5. Debt/Ebitda -1.39 |
| 6. ROIC - WACC (= 1.24)% |
| 7. RoE 8.84% |
| 8. Rev. Trend 67.34% |
| 9. EPS Trend 52.74% |
What is the price of TCMD shares?
Over the past week, the price has changed by +4.27%, over one month by +9.91%, over three months by +101.05% and over the past year by +74.09%.
Is TCMD a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TCMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24 | -21.3% |
| Analysts Target Price | 24 | -21.3% |
| ValueRay Target Price | 32.5 | 6.4% |
TCMD Fundamental Data Overview January 03, 2026
P/E Trailing = 38.1579
P/E Forward = 19.1205
P/S = 2.0793
P/B = 3.1605
P/EG = 17.236
Beta = 0.931
Revenue TTM = 311.5m USD
EBIT TTM = 28.6m USD
EBITDA TTM = 35.4m USD
Long Term Debt = 23.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 3.14m USD (from shortTermDebt, last quarter)
Debt = 16.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -49.2m USD (from netDebt column, last quarter)
Enterprise Value = 598.5m USD (647.7m + Debt 16.7m - CCE 66.0m)
Interest Coverage Ratio = 9.57 (Ebit TTM 28.6m / Interest Expense TTM 2.99m)
FCF Yield = 6.59% (FCF TTM 39.5m / Enterprise Value 598.5m)
FCF Margin = 12.67% (FCF TTM 39.5m / Revenue TTM 311.5m)
Net Margin = 5.83% (Net Income TTM 18.2m / Revenue TTM 311.5m)
Gross Margin = 74.96% ((Revenue TTM 311.5m - Cost of Revenue TTM 78.0m) / Revenue TTM)
Gross Margin QoQ = 75.80% (prev 74.51%)
Tobins Q-Ratio = 2.31 (Enterprise Value 598.5m / Total Assets 259.2m)
Interest Expense / Debt = 1.15% (Interest Expense 193.0k / Debt 16.7m)
Taxrate = 28.22% (3.23m / 11.4m)
NOPAT = 20.6m (EBIT 28.6m * (1 - 28.22%))
Current Ratio = 3.61 (Total Current Assets 141.4m / Total Current Liabilities 39.2m)
Debt / Equity = 0.08 (Debt 16.7m / totalStockholderEquity, last quarter 204.9m)
Debt / EBITDA = -1.39 (Net Debt -49.2m / EBITDA 35.4m)
Debt / FCF = -1.25 (Net Debt -49.2m / FCF TTM 39.5m)
Total Stockholder Equity = 205.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.01% (Net Income 18.2m / Total Assets 259.2m)
RoE = 8.84% (Net Income TTM 18.2m / Total Stockholder Equity 205.5m)
RoCE = 12.52% (EBIT 28.6m / Capital Employed (Equity 205.5m + L.T.Debt 23.2m))
RoIC = 9.15% (NOPAT 20.6m / Invested Capital 224.6m)
WACC = 7.91% (E(647.7m)/V(664.5m) * Re(8.09%) + D(16.7m)/V(664.5m) * Rd(1.15%) * (1-Tc(0.28)))
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.96%
[DCF Debug] Terminal Value 81.29% ; FCFE base≈39.6m ; Y1≈48.8m ; Y5≈83.3m
Fair Price DCF = 62.89 (DCF Value 1.40b / Shares Outstanding 22.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 52.74 | EPS CAGR: 75.57% | SUE: 0.63 | # QB: 0
Revenue Correlation: 67.34 | Revenue CAGR: 9.16% | SUE: 2.62 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.06 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.94 | Chg30d=+0.050 | Revisions Net=+2 | Growth EPS=+17.4% | Growth Revenue=+8.8%
Additional Sources for TCMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle